Medical News

RSS

Protagen, Bayer Schering Pharma close cooperation contract for biomarker discovery in Endometriosis

Protagen AG, a specialist for in-vitro diagnostics and GMP-compliant protein analysis, and Bayer Schering Pharma AG, a global leading specialty pharmaceuticals company, announced today the closing of a cooperation contract for discovery of novel biomarkers in Endometriosis.

10 Jun 2010

Emergency hospital admissions for heart attacks drop by 2.4% following smoke-free legislation

The introduction of smoke-free legislation in England was followed by a 2.4 per cent drop in the number of emergency hospital admissions for heart attacks, new research shows.

10 Jun 2010

Ontario Pharmacists' Association disappointed with government's regulatory changes

The Ontario Pharmacists' Association today expressed concerns and disappointment with the Ontario government's announcement that it is moving ahead with regulatory changes that will significantly reduce support to Ontario pharmacists and their patients.

10 Jun 2010

Dell announces launch of new state health services practice

As states look to understand and address federal regulatory requirements of healthcare reform, Dell Services today announced the launch of a new practice area to help them implement the technology needed to succeed.

10 Jun 2010

Study examines impact of school meals

A thesis from the University of Gothenburg, Sweden, reveals how school initiatives are succeeding in getting the message across to young people, but also points out that food advertisements are using health arguments to market unhealthy products.

10 Jun 2010

Sialidase improves nerve regrowth, motor recovery and nervous system function: Researchers

Once damaged, nerves in the spinal cord normally cannot grow back and the only drug approved for treating these injuries does not enable nerve regrowth. Publishing online this week in the Early Edition of the Proceedings of the National Academy of Sciences, researchers at the Johns Hopkins University School of Medicine show that treating injured rat spinal cords with an enzyme, sialidase, improves nerve regrowth, motor recovery and nervous system function.

10 Jun 2010

PHT, Entra Health partner to provide integrated data monitoring technology for clinical trials in diabetes

PHT Corporation, the leading provider of electronic patient reported outcome (ePRO) solutions today announced a strategic partnership with Entra Health Systems, an international applied healthcare technology company. Together PHT and Entra Health will provide integrated data monitoring technology for the management of clinical trials for the treatment of diabetes and in trials where blood glucose management plays a critical role in the investigation.

10 Jun 2010

Researchers develop new tool for removing blood clots in brain

When someone suffers a stroke, time is critical--more than a million brain cells die each minute, starved of nourishment due to critical damage in a cerebral blood vessel.

10 Jun 2010

Novel gene replacement therapy holds promise for Spinal Muscular Atrophy

Children who suffer from the devastating disease Spinal Muscular Atrophy are set to benefit from a new breakthrough in therapy developments by researchers at the University of Sheffield.

10 Jun 2010

Dyadic signs non-binding term sheet with EnGen Bio for potential outlicense of C1 platform technology

Dyadic International, Inc., a leading biotechnology company focused on the development and manufacture of bioproducts based on its cutting-edge C1 technology to address the needs of multi-billion dollar markets for biofuels, biotherapeutics and industrial enzymes, announced today that it has signed a non-binding term sheet with EnGen Bio, Inc. for a potential outlicense, on an exclusive worldwide basis, of Dyadic's C1 platform technology for applications in biopharmaceutical drug development.

10 Jun 2010

Improvement in Americans' health risk profile will save $945 billion

A 25 percent improvement in the health risk profile of Americans would yield savings of up to $945 billion over the next ten years, according to a report - Savings Potential from Prevention and Risk Reduction for the Commercially Insured- released today by the Center for Health Research (CHR) at Healthways.

10 Jun 2010

Study: ChEI improves driving skills in patients with mild AD

A promising study from Rhode Island Hospital demonstrated that cholinesterase inhibitors, a type of medication often prescribed for Alzheimer's disease, improved some cognitive skills in patients with mild AD - skills that are necessary for driving. Findings from the study showed that after being treated with a ChEI, AD patients improved in some computerized tests of executive function and visual attention, including a simulated driving task.

10 Jun 2010

TF2 bispecific antibody pretargeted therapy prolongs survival in animal model of human colonic cancer

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that pretargeted therapy with TF2, a bispecific antibody against carcinoembryonic antigen (CEA) and a small peptide, delayed tumor growth and prolonged survival in an animal model of human colonic cancer.

10 Jun 2010

Online self-management tool improves asthma patients' ability to reduce their symptoms

An online self-management tool for people with asthma has been shown to significantly improve their ability to reduce their symptoms. Researchers writing in BioMed Central's open access journal Respiratory Research tested the system in 200 adults with asthma, finding significant effects in those whose asthma was either partly controlled or uncontrolled at the beginning of the trial.

10 Jun 2010

ExonHit to pay $12.5M in cash and $10M in stock for RedPath Integrated Pathology acquisition

The extraordinary shareholders' meeting of convened to approve the acquisition of the US company, RedPath Integrated Pathology, will be held on first notice, on Monday, June 28, 2010 at 17:30 CET, at the Company's headquarters, 63-65 boulevard Masséna, 75013 Paris, France. If the quorum is not met, the meeting will be held, on second notice, on July 8, 2010, at 16:00 CET, at the Company's headquarters.

10 Jun 2010

Diabetes expert uses TCOYD to empower people take active role in their condition

Now reaching epidemic proportions, diabetes has led to a significant increase in death and costly complications for approximately 26.2 million people nationwide. But diabetes expert and advocate Dr. Steven Edelman, diagnosed with diabetes at the age of 15, uses his non-profit organization and video series Taking Control of Your Diabetes to empower people to take an active role in their condition.

10 Jun 2010

Xcellerex commences construction of new cGMP FlexFactory biomanufacturing facility at Marlborough

Xcellerex, Inc. announced today that it has begun construction of a state-of-the-art cGMP FlexFactory® biomanufacturing facility at its headquarters location in Marlborough, Massachusetts. Construction will be completed in September 2010. The facility, the second FlexFactory at the company's headquarters site, will expand Xcellerex's capacity to provide bridge biomanufacturing services for clients that are planning or building their own FlexFactory facilities. The plant will also support Xcellerex's contract manufacturing operations.

10 Jun 2010

New study affirms relationship between depression and abdominal obesity

A new study at the University of Alabama at Birmingham confirms the relationship between depression and abdominal obesity, which has been linked to an increased risk for cancer and cardiovascular disease.

10 Jun 2010

CoLucid's lasmiditan NAAMA effective in treatment of acute migraine attacks

CoLucid Pharmaceuticals, Inc.,, an innovative biotechnology company focusing on therapies for central nervous system disorders, today announced that its investigational first-in-class Neurally Acting Anti-Migraine Agent (NAAMA), lasmiditan (also known as COL-144), a selective 5-HT1F receptor agonist, was effective when given orally to treat acute migraine attacks, as documented in a Phase IIb study.

10 Jun 2010

Combination of SIR-Spheres and Sorafenib confers survival benefit for patients with inoperable HCC

A unique combination of liver targeted radioactive microspheres (SIR-Spheres) and a standard-of-care systemic agent (Sorafenib) appears to confer a survival benefit for patients with inoperable primary hepatocellular cancer including those with disease that has spread outside the liver, according to the results of a prospective clinical study presented today at the 46th American Society of Clinical Oncology conference.

10 Jun 2010

Medical News

Protagen, Bayer Schering Pharma close cooperation contract for biomarker discovery in Endometriosis

Emergency hospital admissions for heart attacks drop by 2.4% following smoke-free legislation

Ontario Pharmacists' Association disappointed with government's regulatory changes

Dell announces launch of new state health services practice

Study examines impact of school meals

Sialidase improves nerve regrowth, motor recovery and nervous system function: Researchers

PHT, Entra Health partner to provide integrated data monitoring technology for clinical trials in diabetes

Researchers develop new tool for removing blood clots in brain

Novel gene replacement therapy holds promise for Spinal Muscular Atrophy

Dyadic signs non-binding term sheet with EnGen Bio for potential outlicense of C1 platform technology

Improvement in Americans' health risk profile will save $945 billion

Study: ChEI improves driving skills in patients with mild AD

TF2 bispecific antibody pretargeted therapy prolongs survival in animal model of human colonic cancer

Online self-management tool improves asthma patients' ability to reduce their symptoms

ExonHit to pay $12.5M in cash and $10M in stock for RedPath Integrated Pathology acquisition

Diabetes expert uses TCOYD to empower people take active role in their condition

Xcellerex commences construction of new cGMP FlexFactory biomanufacturing facility at Marlborough

New study affirms relationship between depression and abdominal obesity

CoLucid's lasmiditan NAAMA effective in treatment of acute migraine attacks

Combination of SIR-Spheres and Sorafenib confers survival benefit for patients with inoperable HCC

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Latest News